Crypto bulls are doubling down on a second Trump presidency for this 1 key reason
Read more at MarketWatch
-
Trump doubles down on tariff plan that voters hate
Business - CNBC - October 21 -
Trump's former chief of staff warns of a second presidency
Top stories - CBS News - October 23 -
Trump doubles down on calling Democrats 'enemies from within'
Politics - NBC News - October 16 -
Trump doubles down on 'enemy from within' comments: 'I'm not threatening anybody'
Politics - The Hill - October 16 -
Trump doubles down on ‘enemy within’ rhetoric in final campaign push
Politics - NBC News - October 21 -
Trump doubles down on replacing income taxes with tariffs in Joe Rogan interview
Business - CNBC - October 26 -
2024 election updates: Trump concludes MSG rally with anti-immigrant rhetoric
Top stories - ABC News - October 28 -
Trump doubles down on promise of "largest deportation program in American history"
Top stories - CBS News - October 28
More from MarketWatch
-
Palantir’s stock surges as AI drives a further acceleration in growth
Business - MarketWatch - 2 hours ago -
Marqeta’s stock may shed a third of its value as these factors spur weak outlook
Business - MarketWatch - 2 hours ago -
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
Business - MarketWatch - 2 hours ago -
Dollar Tree’s CEO steps down. An analyst says the move comes at a ‘difficult time.’
Business - MarketWatch - 2 hours ago -
Super Micro needs a new CEO before its AI advantage erodes
Business - MarketWatch - 3 hours ago
Latest in Business
-
Chinese equities outperform ahead of US election
Business - Financial Times - 59 minutes ago -
Trump's tariffs could trigger 'dramatic' price spikes on clothes, furniture, warns retail group
Business - CNBC - 2 hours ago -
Palantir’s stock surges as AI drives a further acceleration in growth
Business - MarketWatch - 2 hours ago -
Marqeta’s stock may shed a third of its value as these factors spur weak outlook
Business - MarketWatch - 2 hours ago -
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
Business - MarketWatch - 2 hours ago